Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Xueling Wu,Zhi Yong Yang,Yuxing Li,Carl Magnus Hogerkorp,William R. Schief,Michael S. Seaman,Tongqing Zhou,Stephen D. Schmidt,Lan Wu,Ling Xu,Nancy S. Longo,Krisha McKee,Sijy O'Dell,Mark K. Louder,Diane Wycuff,Yu Feng,Martha Nason,Nicole A. Doria-Rose,Mark Connors,Peter D. Kwong,Mario Roederer,Richard T. Wyatt,Gary J. Nabel,John R. Mascola +23 more
Reads0
Chats0
TLDR
Three broadly neutralizing antibodies are identified, isolated from an HIV-1–infected individual, that exhibited great breadth and potency of neutralization and were specific for the co-receptor CD4-binding site of the glycoprotein 120 (gp120), part of the viral Env spike.Abstract:
Cross-reactive neutralizing antibodies (NAbs) are found in the sera of many HIV-1-infected individuals, but the virologic basis of their neutralization remains poorly understood. We used knowledge of HIV-1 envelope structure to develop antigenically resurfaced glycoproteins specific for the structurally conserved site of initial CD4 receptor binding. These probes were used to identify sera with NAbs to the CD4-binding site (CD4bs) and to isolate individual B cells from such an HIV-1-infected donor. By expressing immunoglobulin genes from individual cells, we identified three monoclonal antibodies, including a pair of somatic variants that neutralized over 90% of circulating HIV-1 isolates. Exceptionally broad HIV-1 neutralization can be achieved with individual antibodies targeted to the functionally conserved CD4bs of glycoprotein 120, an important insight for future HIV-1 vaccine design.read more
Citations
More filters
Journal ArticleDOI
An Intravaginal Ring for the Sustained Delivery of Antibodies
TL;DR: A novel pod-IVR platform that delivers ovine IgG (ov-IgG) as a model for IgG and IgA human mAbs enables a new arsenal of topical biologic microbicide candidates beyond small molecule antiretrovirals and significantly broadens the range of microbicides that can be delivered in a sustained fashion from IVRs.
Journal ArticleDOI
Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies
Jenniffer M. Mabuka,Jenniffer M. Mabuka,Anne-Sophie Dugast,Daniel M. Muema,Daniel M. Muema,Tarylee Reddy,Yathisha Ramlakhan,Zelda Euler,Nasreen Ismail,Amber Moodley,Amber Moodley,Krista L. Dong,Krista L. Dong,Lynn Morris,Bruce D. Walker,Galit Alter,Thumbi Ndung'u +16 more
TL;DR: Hyperacute HIV-1 infection is associated with B cell subset changes, which do not predict emergence of cross-neutralizing antibodies, but plasma CXCL13 levels during hyperacute infection predicted the subsequent emergence ofCross-neutralization antibodies, providing a potential biomarker for the evaluation of vaccines designed to elicit cross- neutralizing activity or for natural infection studies to explore mechanisms underlying development of neutralizing antibodies.
Journal ArticleDOI
New pharmacological strategies to fight enveloped viruses
TL;DR: This review focuses on recent developments to generate antivirals targeting host cell factors or immune-based therapeutic approaches to fight infections with enveloped viruses.
Journal ArticleDOI
Vaccinology: precisely tuned antibodies nab HIV.
Paul R. Clapham,Shan Lu +1 more
TL;DR: The isolation of a new panel of monoclonal antibodies with broad neutralizing activity against HIV that could be promising as immunotherapeutics is reported, and some are ten times more potent than previously reported antibodies.
Journal ArticleDOI
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization
Kathryn M. Hastie,Robert W. Cross,Stephanie Harkins,Stephanie Harkins,Michelle Zandonatti,Michelle Zandonatti,Anatoliy P. Koval,Megan L. Heinrich,Megan M. Rowland,James E. Robinson,Thomas W. Geisbert,Robert F. Garry,Luis M. Branco,Erica Ollmann Saphire,Erica Ollmann Saphire +14 more
TL;DR: The ability to define antibody residues that allow potent and broad neutralizing activity, together with findings from analyses of inferred germline precursors, is critical to develop potent therapeutics and for vaccine design and assessment.
References
More filters
Journal ArticleDOI
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
Peter D. Kwong,Richard T. Wyatt,James E. Robinson,Raymond W. Sweet,Joseph Sodroski,Wayne A. Hendrickson,Wayne A. Hendrickson +6 more
TL;DR: The structure reveals a cavity-laden CD4–gp120 interface, a conserved binding site for the chemokine receptor, evidence for a conformational change upon CD4 binding, the nature of a CD4-induced antibody epitope, and specific mechanisms for immune evasion.
Journal ArticleDOI
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
Brandon F. Keele,Elena E. Giorgi,Elena E. Giorgi,Jesus F. Salazar-Gonzalez,Julie M. Decker,Kimmy T. Pham,Maria G. Salazar,Chuanxi Sun,Truman Grayson,Shuyi Wang,Hui Li,Xiping Wei,Chunlai Jiang,Jennifer L. Kirchherr,Feng Gao,Jeffery A. Anderson,Li Hua Ping,Ronald Swanstrom,Georgia D. Tomaras,William A. Blattner,Paul A. Goepfert,J. Michael Kilby,Michael S. Saag,Eric Delwart,Michael P. Busch,Myron S. Cohen,David C. Montefiori,Barton F. Haynes,Brian Gaschen,Gayathri Athreya,Ha Y. Lee,Natasha T. Wood,Cathal Seoighe,Alan S. Perelson,Tanmoy Bhattacharya,Tanmoy Bhattacharya,Bette T. Korber,Bette T. Korber,Beatrice H. Hahn,George M. Shaw +39 more
TL;DR: A mathematical model of random viral evolution and phylogenetic tree construction is developed and used to analyze 3,449 complete env sequences derived by single genome amplification from 102 subjects with acute HIV-1 (clade B) infection, suggesting a finite window of potential vulnerability of HIV- 1 to vaccine-elicited immune responses, although phenotypic properties of transmitted Envs pose a formidable defense.
Journal ArticleDOI
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Laura M. Walker,Sanjay Phogat,Po-Ying Chan-Hui,Denise Wagner,Pham Phung,Julie L. Goss,Terri Wrin,Melissa Simek,Steven P. Fling,Jennifer L. Mitcham,Jennifer Lehrman,Frances Priddy,Ole A. Olsen,Steven Frey,Phillip W. Hammond,Protocol G. Principal Investigators,Stephen M. Kaminsky,Timothy J. Zamb,Matthew Moyle,Wayne C. Koff,Pascal Poignard,Dennis R. Burton,Dennis R. Burton +22 more
TL;DR: High-throughput screening has revealed two new broadly neutralizing antibodies from a clade A–infected donor in Africa, which exhibit great potency and are able to neutralize a wide range of viruses from many different clades.
Journal ArticleDOI
Design of a Novel Globular Protein Fold with Atomic-Level Accuracy
TL;DR: A general computational strategy that iterates between sequence design and structure prediction to design a 93-residue α/β protein called Top7 with a novel sequence and topology, found experimentally to be folded and extremely stable.
Journal ArticleDOI
The antigenic structure of the HIV gp120 envelope glycoprotein
Richard T. Wyatt,Peter D. Kwong,Elizabeth Desjardins,Raymond W. Sweet,James E. Robinson,Wayne A. Hendrickson,Joseph Sodroski +6 more
TL;DR: The spatial organization of conserved neutralization epitopes on gp120 is described, using epitope maps in conjunction with the X-ray crystal structure of a ternary complex that includes a gp120 core, CD4 and a neutralizing antibody.
Related Papers (5)
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
Laura M. Walker,Sanjay Phogat,Po-Ying Chan-Hui,Denise Wagner,Pham Phung,Julie L. Goss,Terri Wrin,Melissa Simek,Steven P. Fling,Jennifer L. Mitcham,Jennifer Lehrman,Frances Priddy,Ole A. Olsen,Steven Frey,Phillip W. Hammond,Protocol G. Principal Investigators,Stephen M. Kaminsky,Timothy J. Zamb,Matthew Moyle,Wayne C. Koff,Pascal Poignard,Dennis R. Burton,Dennis R. Burton +22 more
Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M. Walker,Michael Huber,Michael Huber,Katie J. Doores,Katie J. Doores,Emilia Falkowska,Emilia Falkowska,Robert Pejchal,Jean-Philippe Julien,Sheng-Kai Wang,Alejandra Ramos,Po-Ying Chan-Hui,Matthew Moyle,Jennifer L. Mitcham,Phillip W. Hammond,Ole A. Olsen,Pham Phung,Steven P. Fling,Chi-Huey Wong,Sanjay Phogat,Terri Wrin,Melissa Simek,Protocol G. Principal Investigators,Wayne C. Koff,Ian A. Wilson,Dennis R. Burton,Dennis R. Burton,Pascal Poignard,Pascal Poignard +28 more
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.
Johannes F. Scheid,Hugo Mouquet,Beatrix Ueberheide,Ron Diskin,Florian Klein,Thiago Y. Oliveira,John Pietzsch,John Pietzsch,David Fenyö,Alexander Abadir,Klara Velinzon,Arlene Hurley,Sunnie Myung,Farid Boulad,Pascal Poignard,Pascal Poignard,Dennis R. Burton,Dennis R. Burton,Florencia Pereyra,Florencia Pereyra,David D. Ho,Bruce D. Walker,Bruce D. Walker,Bruce D. Walker,Michael S. Seaman,Pamela J. Bjorkman,Pamela J. Bjorkman,Brian T. Chait,Michel C. Nussenzweig,Michel C. Nussenzweig +29 more
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.
Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand
Supachai Rerks-Ngarm,Punnee Pitisuttithum,Sorachai Nitayaphan,Jaranit Kaewkungwal,Joseph Chiu,Robert Paris,Nakorn Premsri,Chawetsan Namwat,Mark de Souza,Elizabeth Adams,Michael Benenson,Sanjay Gurunathan,Jim Tartaglia,John G. McNeil,Donald P. Francis,Donald Stablein,Deborah L. Birx,Supamit Chunsuttiwat,Chirasak Khamboonruang,Prasert Thongcharoen,Merlin L. Robb,Nelson L. Michael,Prayura Kunasol,Jerome H. Kim +23 more